

1 Article

# 2 Discovering methylation markers and development of a 3 sense-antisense and dual-MGB probe PCR assay in plasma for 4 colorectal cancer early detection

5 Yanteng Zhao<sup>1†\*</sup>, Zhijie Wang<sup>2†</sup>, Qiuning Yu<sup>3</sup>, Xin Liu<sup>1</sup>, Xue Liu<sup>1</sup>, Shuling Dong<sup>1</sup>, Xianping Lv<sup>1</sup>, Tiao Zhang<sup>4</sup>, Dihan  
6 Zhou<sup>5</sup>, Qiankun Yang<sup>1\*</sup>

7 <sup>1</sup> Department of Transfusion, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

8 <sup>2</sup> Department of Gastroenterology, Affiliated Hangzhou First People's Hospital, West  
9 lake University School of Medicine, Hangzhou 310003, China;

10 <sup>3</sup> Otorhinolaryngology Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China;

11 <sup>4</sup> Chongqing International Travel Healthcare Center (Chongqing Customs Port Outpatient), Chongqing 4001147, China;

12 <sup>5</sup> Wuhan Ammunition Life-tech Company, Ltd., Wuhan 430200, China;

13 † These authors contributed equally to this work

14 \* Correspondence: [zyt198910066@126.com](mailto:zyt198910066@126.com); [yqiankun@126.com](mailto:yqiankun@126.com)

16 **Abstract:** Screening for colorectal cancer (CRC) using plasma methylation is challenging due to  
17 the low abundance of cell-free DNA (cfDNA). Therefore, the development of signal amplification  
18 assays based on appropriate markers is essential to increase sensitivity. In this study, we  
19 employed an epigenome-wide approach for de novo identification differentially methylated CpGs  
20 (DMCs) common to CRC and adenoma using 17 public datasets. A sense-antisense and dual MGB  
21 probe (SADMP) assay was then developed. Subsequently, the biomarkers were validated in 712  
22 plasma samples based on SADMP. A total of 2237 DMCs showed overlap between CRC and  
23 adenoma. Of these, 75 were hypomethylated in 30 other non-CRC cancers. Following LASSO  
24 regression, WBC validation and primer/probe design evaluation, *NTMT1* and *MAP3K14-AS1* were  
25 identified as the most informative candidate biomarkers. At preset template concentrations, the  
26 SADMP assay for *NTMT1* or *MAP3K14-AS1* could reduce the cycle threshold by 1. The *NTMT1*  
27 and *MAP3K14-AS1* dual-target SADMP assay demonstrated a sensitivity of 84.8% for CRC (stage I:  
28 75.0%), a sensitivity of 32.0% for advanced adenomas (AA), and a specificity of 91.5% in controls.  
29 The dual-target assay showed high performance for CRC early detection in plasma, suggesting  
30 that it may serve as a promising noninvasive tool for CRC screening.

31 **Keywords:** colorectal cancer; cell-free DNA; methylation; early detection; methylation-specific  
32 PCR

45

## 1. Introduction

46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65

The majority of early-stage advanced colorectal neoplasms, including colorectal cancer (CRC) and advanced adenoma (AA) are curable, particularly AA, which can be removed at the time of diagnosis by colonoscopy. Consequently, the early detection of CRC and AA represents a highly valuable endeavor. A number of tests based on cell-free DNA (cfDNA) methylation have been developed and have shown good performance for CRC detection. Epi proColon [1] is the first blood-based test utilized for the early detection of CRC and was developed based on methylated cfDNA of *Septin9*. The updated version of Epi proColon® 2.0 CE demonstrated an improved sensitivity of 74.8%-81% and specificity of 96.3%-99% in a prospective cohort study [2]. The Chinese version of Epi proColon simplified sample processing with a single reaction system in a larger volume (60 ul) instead of a 2/3 algorithm (20 ul for three runs), resulting a sensitivity of 73% and a specificity of 94.5% [3]. However, its sensitivity for detecting polyps or AA was relatively low in most studies, ranging from 8-40% [4-6]. Due to this relatively poor sensitivity, particularly for precancerous lesions, the US Preventive Services Task Force and the American Cancer Society currently do not include the test in their CRC screening guidelines. Moreover, plasma methylated *Septin9* is not a CRC specific marker but showed an ability to detect multiple cancer types, including hepatocellular carcinoma [7], gastric cancer [8], cervical cancer [9], and breast cancer [10]. Therefore, developing a sensitive and specific blood assay for CRC screening is meaningful.

66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84

Due to the disparate mechanisms by which cancer signals enter the blood and stool, it is probable that the markers are not universal, and the accuracy of CRC markers in the blood is typically low in comparison to those in stool. Consequently, an ab initio search for blood methylation markers for early CRC and AA is imperative. Furthermore, the detection of the methylation signal of cell-free tumor DNA (ctDNA) in plasma is challenging due to the presence of ctDNA fragments released by multiple organs or tissues, as well as DNA damage caused by bisulfite conversion [11]. Therefore, the identification of suitable markers and the development of effective detection techniques are essential to ensure optimal performance [12]. Classical PCR-based methylation detection techniques are often developed based on single-strand bisulfite converted DNA (BS-DNA), leaving the information of the other strand unused [13]. Furthermore, only one Taqman MGB probe is usually designed to provide fluorescent signals. Theoretically, designing primers for both sense and antisense strand DNA simultaneously or using multiple MGB probes will improve the sensitivity of a marker to detect methylation signals by enhancing fluorescent signals. Sarah Ø. Jensen et al [14] made the first attempt to design a pair of primers for both sense and antisense strands, thereby enhancing the performance of three targets for CRC detection. Additionally, the dual-strand technique was also successfully applied to methylated *HOXA9* in ovarian cancer to improve the detection sensitivity [15].

85  
86  
87  
88  
89  
90  
91  
92

In this study, we utilized all publicly available methylation data for CRC and adenomas to identify methylation markers, with a particular focus on those that are hypermethylated in adenomas. Furthermore, in order to enhance the ability of candidate markers to detect low-abundance cfDNA methylation signals in plasma, we attempted to apply dual-strand and dual-MGB probe techniques simultaneously, which we called the sense-antisense and dual-MGB probe (SADMP) technique, to develop a novel CRC plasma test. Finally, the test performance was comprehensively assessed in our recruited training and validation cohorts.

93

## 2. Materials and Methods

94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121

### 2.1. Data preparation

Thirteen methylation datasets, which were GSE77954, GSE101764, GSE131013, GSE199057, GSE164811, GSE193535, GSE129364, GSE139404, GSE107352, GSE75546, GSE77965, GSE68060 and EMTAB6450 from public databases were selected based on three criteria: 1) were generated by Illumina HumanMethylation 450k BeadChip and had the raw IDAT files, 2) the sample size was greater than 10, and 3) consisted of CRC or adenoma or normal adjacent tissue (NAT). All the IDAT files were then processed using the minfi tool [16] to obtain methylation  $\beta$  values. They were integrated as a single dataset (n= 1165), which we defined as Phase I discovery set for candidate marker identification.

Level 3 methylation data for 31 cancer types were retrieved from The Cancer Genome Atlas (TCGA) database (<https://portal.gdc.cancer.gov/>). Data for 8258 primary tumor tissues corresponding to 31 cancer types and their 710 NATs were retained. The 31 cancer types included ACC (n=79), BLCA (n=412), BRCA (n=778), CESC (n=306), CHOL (n=36), CRC (n=379), DLBC (n=48), ESCA (n=183), GBM (n=137), HNSC (n=523), KICH (n=65), KIRC (n=312), KIRP (n=271), LGG (n=513), LIHC (n=374), LUAD (n=456), LUSC (n=364), MESO (n=87), OV (n=10), PAAD (n=183), PCPG (n=178), PRAD (n=495), SARC (n=257), SKCM (n=104), STAD (n=393), TGCT (n=133), THCA (n=503), THYM (n=124), UCEC (n=418), UCS (n=57), UVM (n=80). The TCGA dataset was defined as Phase II discovery dataset. DMCs were deemed eligible if they exhibited methylation levels <0.2 on other cancer types (non-CRC),  $\geq$ 0.55 on CRC, and <0.15 on 710 NATs.

The other three datasets, GSE48684 [17], GSE40279 [18], and GSE122126 [19], generated by the same platform of Illumina HumanMethylation BeadChip in Gene Expression Omnibus (GEO) were used as validation sets to verify the methylation status of candidate differentially methylated CpGs (DMCs). The GSE48684 cohort consisted of 105 qualified samples, of which 41 were NAT and 64 were CRC. The GSE40279 cohort comprised whole blood cell (WBC) samples collected from 656 healthy individuals. The GSE122126 cohort included three CRC and 12 normal plasma samples.

122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140

### 2.2. Sample collection

This case-control study enrolled 772 cases, including 60 tissue samples (30 CRC and 30 NATs) and 712 plasma samples from the First Affiliated Hospital of Zhengzhou University between April 2022 and June 2022. Tissue samples were obtained from the preserved formalin-fixed paraffin-embedded (FFPE) sections collected from surgical patients. The plasma cohort was randomly divided into a training set and a validation set in a 2:1 ratio. The training set comprised 474 participants, including 115 healthy blood donors, 123 non-digestive disease patients (NDD), 65 intestinal disease patients (ID), 14 polyps patients, 10 non-advanced adenoma patients (Non-AA), 16 AA, 125 CRC patients, and 6 patients with other cancers. In the validation set, there were 235 participants, including 57 healthy blood donors, 60 NDD, 30 intestinal ID, 6 polyps patients, 5 Non-AA, 9 AA, 66 CRC patients, and 2 patients with other cancers (**Supplemental Table 1**). This study is a sub-project of the Clinical Study of Pan-cancer DNA Methylation Test in plasma (Clinical Trials ID: NCT05685524). Patients with polyps, adenomas, CRC and other cancers were confirmed by histopathological examinations. The included CRC patients were required to meet the following criteria: 1) did not receive any radiotherapy, chemotherapy or surgery, 2) ages older than 18. All CRC patients were classified as I, II, III, and IV stages according to the American Joint Cancer Committee (AJCC) staging system.

141  
142  
143

### 2.3. Differential methylation analysis

We performed differential methylation analysis using the rank-sum test on three groups in the discovery set: cancer vs. normal (NAT), adenoma vs. normal, and cancer

144 vs. adenoma. DMCs were defined as significant if they meet two criteria: an FDR < 0.05  
145 and a fold change ranking in the top 1% of all probes. The DMCs were then classified as  
146 hyper- or hypo- DMCs based on whether they exhibited high or low methylation levels  
147 in the tumor or adenoma samples compared to the normal samples. LASSO regression  
148 was implemented in the R package 'glmnet' to reduce the number of features. LASSO  
149 regression was repeated 100 times, and the frequencies of probes with non-zero  
150 coefficients in the regressions were counted.

#### 151 2.4. Tissue and plasma DNA extraction

152 Genomic DNA from tissue samples and plasma cfDNA was isolated using the FFPE  
153 DNA rapid extraction kit (TianGen, Beijing) and the plasma/serum cfDNA extraction kit  
154 (Ammunition Life-tech, Wuhan), respectively, according to the protocols. Briefly, cfDNA  
155 extraction was divided into two steps. First, approximately 10 ml of blood was drawn  
156 from participants at room temperature and then centrifuged twice with 1300g and  
157 14000g for 10 min at 4°C within 2 hours. Then, about 2 ml of plasma was retained for  
158 cfDNA purification. Purified cfDNA was eluted in 45 ul TE buffer and then treated with  
159 bisulfite using a DNA bisulfite modification kit (Ammunition Life-tech, Wuhan) in  
160 accordance with the instructions described in the aforementioned study [20], or stored at  
161 -80 °C until required.

#### 162 2.5. Sanger sequencing

163 Sanger sequencing (ABI 3730XL, GENEWIZ, Suzhou) was performed for the target  
164 regions of *NTMT1* and *MAP3K14-AS1* after bisulfite treatment to confirm their  
165 methylation status on 30 CRC tissue samples and 30 NATs. The sequencing primers are  
166 shown in **Supplemental Table 2**. Following bisulfite treatment, cytosine in methylated  
167 CpG sites remained cytosine, while unmethylated cytosine was converted to thymine.  
168 Sanger sequencing results thus allowed for the direct determination of the methylation  
169 status of target regions.

#### 170 2.6. Developing the SADMP and methylation-specific PCR (MSP) technique

171 The location and sequences of MSP primers/ probes are displayed in **Supplemental**  
172 **Table 3**. For *NTMT1*, two pairs of methylation primers targeted the sense and antisense  
173 strands, and their corresponding MGB probes were designed. For *MAP3K14-AS1*, the  
174 MGB-probe 1 and MGB-probe 2 were designed according to the antisense strand  
175 sequence and the reverse complementary sequence of the antisense strand.

176 Gradient dilutions of synthetic plasmids or plasmid mixtures are employed as  
177 templates for the determination of test parameters. Specifically, standard curve  
178 experiments were carried out to assess the amplification efficiency of each pair of  
179 primers. The experiments consisted of five ten-fold dilutions of fully methylated  
180 plasmid DNA templates with five replicates at each dilution (1, 10, 100, 1000, and 10000  
181 copies per run). Primer tolerance experiments were designed to assess the specific  
182 amplification ability of methylated primers against methylated templates. Eight  
183 concentration dilutions of fully methylated DNA templates (0, 1, 5, 10, 50, 100, 200, and  
184 400 copies/ $\mu$ L) mixed with a high concentration of unmethylated plasmid ( $10^7$  copies/ $\mu$ L)  
185 were prepared to evaluate the ability of methylated primers selectively amplifying  
186 methylated templates under the background of unmethylated templates. Each  
187 concentration experiment was repeated five times.

188 The amplification system of MSP was shown in **Supplemental Table S4**. The test  
189 employed a triplex PCR with a FAM channel for the internal reference gene *ACTB*, a  
190 ROX channel for *NTMT1* (dual-strands), and VIC channel for *MAP3K14-AS1* (dual-MGB  
191 probes). The PCR procedure was pre-denaturation at 95°C for 5 min (step 1),  
192 denaturation at 95°C for 15s (step 2), annealing at 60°C for 30s (step 3), repeating step 2

193 and 3 forty-five times in plasmid samples and fifty times in plasma samples on the 7500  
194 Fast Real-Time PCR System (Applied Biosystems, USA), the cycle threshold (Ct) was  
195 assigned to 45 or 50 for the target without amplification.

### 196 2.7. Statistical analysis

197 The data processing and analysis in this study were conducted using R software  
198 (version 4.1.0). The 'glm' function was employed to fit the logistic regression model with  
199 a parameter of 'family=binomial'. Receiver operating characteristic (ROC) curve analysis  
200 was performed using the 'pROC' package, and the area under the ROC curve (AUC)  
201 was subsequently calculated to assess the test classification performance. The optimal  
202 sensitivity and specificity of the test were estimated when Youden's index reached its  
203 maximal value. Sensitivity and specificity were calculated using the following formulas:  
204

$$\text{sensitivity} = \frac{\text{True positive}}{\text{True positive} + \text{False negative}}$$
$$\text{specificity} = \frac{\text{True negative}}{\text{True negative} + \text{False positive}}$$


205 And the Youden index = sensitivity+specificity-1.

206 The rank-sum test and Kruskal test were employed for the comparisons between  
207 two groups and the comparisons between multiple groups, respectively. The Chi-square  
208 test was utilized for the comparisons between categorical variables. The Other statistical  
209 methods used in this study were described in the corresponding results.  
210  
211

## 212 3. Results

### 213 3.1. Study design and participant characteristics


214 The study is divided into four steps, as illustrated in **Figure 1**. In the initial step,  
215 candidate markers were identified in a set of 1165 samples from 13 datasets. Of these,  
216 452 were normal, 168 were adenomas, and 545 were CRC. These markers were then  
217 narrowed down using data from 31 cancer types in the TCGA dataset, DMCs that were  
218 hypermethylated in cancer other than CRC were filtered out. The available DMCs were  
219 further validated in three independent datasets. In the second step, the methylation  
220 status of candidate CpGs was confirmed by Sanger sequencing using 30 CRC tissues and  
221 30 NATs. In the third step, the SADMP technique and MSP system were established.  
222 This involved designing appropriate primers, optimizing the qPCR amplification system,  
223 and evaluating the technical parameters of the assay. In the last step, the developed  
224 assay was tested on training and validation sets of plasma. Its performance was assessed  
225 by estimating indicators such as sensitivity, specificity, and AUC.



226  
227 **Figure 1.** The flowchart of this study. The four steps were illustrated by different colored blocks.

228  
229  
230 **3.2. Landscape of the methylation patterns of the 13 discovery datasets**

231 The methylation levels of adenoma and cancer samples were found to be lower  
232 than normal, as shown in **Figure 2A**. The methylation density curves for the three  
233 groups displayed bimodal distributions with hyper- and hypomethylation peaks,  
234 respectively (**Figure 2B**). The hyper-methylation peaks of adenoma and tumor samples  
235 were lower than those of normal samples, indicating higher methylation levels in  
236 normal samples.



237  
238 **Figure 2.** Landscape of the methylation patterns of the phase I discovery set.

239 (A) boxplot showing the overall methylation levels of normal, adenoma and cancer samples. The  
240 average  $\beta$  value of all probes for each sample was calculated as the sample overall methylation  
241 level. P-values were estimated by Kruskal test. (B) Density curves of probe methylation levels in  
242 normal, adenoma and cancer samples. (C) t-SNE visualizing normal, adenoma and cancer samples  
243 in the discovery set. (D) Heatmap showing the most variable probes between normal, adenoma  
244 and cancer samples.


245  
246 We employed t-SEN to analyze and visualize the structure of the discovery set and  
247 identified significant differences between normal and cancer samples. However,  
248 adenomas exhibited overlap with both normal and cancer samples (Figure 2C). We then  
249 selected the top 1% of most variable probes to cluster the discovery set using the  
250 K-means algorithm. The results showed that both normal and cancer samples clustered  
251 together, while adenomas were separated into two subgroups with a remarkable  
252 difference. They showed both high (Methy-H) and low (Methy-L) methylation status  
253 and were closer to cancer and normal samples, respectively (Figure 2D).

254 Further analysis revealed that tubular adenomas constituted the largest proportion  
255 of Methy-L adenomas (23/57 or 40.35%), while villous adenomas constituted the largest  
256 proportion of Methy-H adenomas (47/73 or 64.38%). To eliminate any potential bias  
257 between the datasets, we conducted Fisher's test separately for the Methy-H and  
258 Methy-L adenomas, with the datasets serving as the stratification factor. However, we  
259 did not identify any significant differences ( $P > 0.05$ ).  
260

### 261 3.3. Identification of candidate DMCs

262 First, we conducted a comparative analysis of the DMCs between cancer, adenoma,  
263 and normal samples using the 13 discovery datasets. The three comparisons (cancer vs.  
264 normal, adenoma vs. normal, and cancer vs. adenoma) yielded 3000, 3051, and 1545  
265 DMCs, respectively. Notably, these DMCs were predominantly hyper-DMCs (**Figure**  
266 **3A**). Further investigations revealed that the majority of DMCs were distributed in  
267 upstream regions of genes (5'UTR, TSS1500, TSS500, and 1st Exon), except for cancer vs.  
268 adenoma where DMCs were mainly located in gene bodies (**Figure 3B**). We observed an  
269 extremely high proportion of overlapping DMCs between cancer vs. normal and  
270 adenoma vs. normal, which was significantly higher than cancer vs. adenoma (**Figure**  
271 **3C**). To identify the most appropriate DMCs, we focused on those that were overlapped  
272 between cancer vs. normal and adenoma vs. normal (2237 probes) and evaluated their  
273 methylation levels on 31 cancer types of TCGA. This yielded 75 accessible probes  
274 (**Figure 3D**). LASSO regression was employed to reduce the number of DMCs, with  
275 eight presented in 100 replicates with non-zero coefficients (**Figure 3E**).





**Figure 3.** Identification of candidate markers. **(A)** Percentage of hyper-DMC and hypo-DMC between the three comparisons. **(B)** Percentage of DMC at different genomic regions between the three comparisons. **(C)** Venn diagram showing DMCs between the three comparisons. **(D)** Methylation values of 75 probes meeting the criteria on TCGA 31 cancer types. The “other” refers to 30 non-CRC cancer samples. “Normal” refers to 710 NATs. **(E)** Frequency of probes with non-zero coefficient in 100 LASSO regressions.

### 3.4. The methylation levels of *NTMT1* and *MAP3K14-AS1* in validation sets

The methylation levels of the eight probes were then analyzed in 656 WBC samples, and seven DMCs exhibited relatively low methylation levels (less than 0.1) with the exception of cg17892556 (**Figure 4A**). Therefore, the seven DMCs are recognized as the most promising markers.

Two specific DNA methylation sites, cg14015706 and cg08247376, were selected for further analysis as they were suitable for primer/probe design. These sites are located in the first exon of *NTMT1* and 200 bp upstream of the *MAP3K14-AS1* transcription start site, respectively. The GSE48684 dataset revealed significantly higher methylation levels

276

277

278

279

280

281

282

283

284

285

286

287

288


289

290

291

292  
293  
294  
295

for both probes in cancer samples than in normal samples (**Figure 4B**). Furthermore, the two probes demonstrated hypermethylation in CRC plasma and hypomethylation in healthy plasma (**Figure 4C**), indicating a high consistency of the methylation status between tissue and plasma.



296  
297  
298  
299  
300  
301  
302

**Figure 4.** Methylation profiles of the two candidate probes in different datasets. **(A)** The methylation profiles of cg14015706 and cg08247376 in 656 healthy WBC in GSE40279. **(B)** The methylation  $\beta$  values of cg14015706 and cg08247376 between normal and cancer samples in GSE48684 dataset. **(C)** The cfDNA methylation profiles of cg14015706 and cg08247376 in normal and cancer plasma samples from GSE122126. Numbers in the heatmap indicated the methylation  $\beta$  values.

303


304

### 3.5. The SADMP technique

305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320

The Sanger sequencing of the target regions revealed that the CpGs sites among the amplicons were more frequently methylated in CRC than NATs, which provided the foundation for the development of SADMP technique. For *NTMT1*, two pairs of methylation primers targeted the sense and antisense strands, and their corresponding MGB probes were designed (**Figure 5A**). For *MAP3K14-AS1*, the MGB-probe1 and MGB-probe2 were designed according to the antisense strand sequence and the reverse complementary sequence of antisense strand (**Figure 5F**). The estimated amplification efficiencies of *NTMT1* and *MAP3K14-AS1* were 98.14% and 110.08%, respectively (**Figure 5B** and **5G**). The sense and anti-sense strands were transformed into completely different DNA sequences after bisulfite treatment and both could be used as PCR templates. It can be postulated that the copy numbers detected by any single pair of primers or single MGB-probe assay should be half of the diluted copy numbers calculated as the sum of sense and anti-sense strand templates, and that the SADMP assay should be equal to the diluted copy numbers. For *NTMT1*, the detected copy numbers by sense and antisense strand assays were slightly less than half of the theoretical copy numbers with slopes of 0.39 and 0.31, respectively. The detected copy

numbers by dual-strand assay were approximately 0.73 times of theoretical copy numbers, which was approximately two-fold compared to any single-strand assay (Figure 5C), as expected. Meanwhile, Ct value of dual-strand assay was almost one cycle earlier than that of any single-strand assay (average  $\Delta Ct=1.21$ , Figure 5D), which was consistent with the theoretical  $\Delta Ct$  value (should be one). The *MAP3K14-AS1* SADMP showed similar results, with the number of copies detected was doubled compared to the single probe assay (Figure 5H), and the Ct values were shifted forward by 0.99 cycles (Figure 5I).




332 **Figure 5.** The development and validation of SADMP. **(A)** SADMP strategy for *NTMT1*. Two pairs  
333 of primers were designed according to the sense and antisense BS-strand sequences. CBS indicated  
334 the complementary sequence of sense and antisense BS-strands. **(B)** The standard amplification  
335 curve of *NTMT1*. **(C)** The agreement between detected copies by SADMP and single-strand assays  
336 and diluted template DNA copies (theoretical copies) of *NTMT1*. The solid lines were fitted by a  
337 simple linear model. **(D)** and **(E)** The detected Ct values of SADMP *NTMT1* and single-strand  
338 *NTMT1* assays for different diluted concentrations. **(F)** SADMP strategy for *NTMT1*. Two MGB  
339 probes were designed. Probe 1 is located downstream of the forward primer, targeting the  
340 BS-strand template. Probe 2 is located downstream of the reverse primer, targeting the  
341 complementary sequence of BS-strand. **(G)** The standard amplification curve of *MAP3K14-AS1*. **(H)**  
342 The agreement between detected copies by SADMP and single-probe assays and diluted template  
343 DNA copies (theoretical copies) of *MAP3K14-AS1*. The solid lines were fitted by a simple linear  
344 model. **(I)** and **(J)** The detected Ct values of SADMP *MAP3K14-AS1* and single-probe  
345 *MAP3K14-AS1* assays for different diluted concentrations.

346  
347 Additionally, in the serially diluted experiment, no amplification curves for both  
348 targets were observed when a high proportion of unmethylated DNA was used as  
349 templates (the methylated DNA copies were 0) (**Figure 5E** and **5G**). These results  
350 suggested that the developed assays were explicitly targeted for methylated DNAs even  
351 at the high background of unmethylated DNAs. We also found that the *NTMT1* SADMP  
352 assay was able to robustly detect methylated DNAs at a concentration of 10 copies/ $\mu$ L  
353 (**Figure 5E**), while it was 5 copies/ $\mu$ L for the *MAP3K14-AS1* SADMP (**Figure 5G**).

### 354 3.6. Validation and evaluation of biomarkers using MSP in plasma samples

355 In the plasma sample set, the Ct values of *ACTB* exhibited a slight decrease in trend  
356 from the healthy control groups to the cancer group ( $p < 0.0001$ ) (**Figure 6A**). Ct values  
357 of *NTMT1* and *MAP3K14-AS1* were much lower in CRC samples and AA samples than  
358 other control groups (**Figure 6B** and **6C**).



**Figure 6.** dual-target assessment and validation in plasma samples. (A-C) Ct values of *ACTB* (A), *NTMT1* (B) and *MAP3K14-AS1* (C) in various clinical groups. NDD: Non-digestive disease, ID: Intestinal disease, AA: advanced adenoma. The eight groups were compared by Kruskal-Wallis test.  $P < 0.05$  is considered significant. \*\*\*\* is  $p < 0.0001$ . (D-E) ROC curves of two biomarkers in CRC vs Control groups (D) and CRC+AA vs Control groups (E) in training set. (F-G) Sensitivity and specificity of individual biomarker and dual-target in training set (F), validation set (G) and total set (H) using 1/2 algorithm. Error bars represent 95% CI.

The Ct values could discriminate the CRC and AA samples from healthy samples very well. Furthermore, the Ct values-based result determination exhibited favorable outcomes in a previous study [21,22]. Consequently, the Ct values were utilized as the result analysis indicators. In order to determine the algorithm and cutoff, ROC curve

359

360

361

362

363

364

365

366

367

368

369

370

371

analysis was conducted in the training set. In the CRC vs control groups, the AUC values for *NTMT1* and *MAP3K14-AS1* were 0.882 (95% CI: 0.838-0.925) and 0.785 (95% CI: 0.729-0.840), respectively (**Figure 6D**). In the CRC+AA vs control groups, the AUC values for *NTMT1* and *MAP3K14-AS1* were 0.852 (95% CI: 0.807-0.898) and 0.761 (95% CI: 0.707-0.815), respectively (**Figure 6E**).

As AA was precancerous lesions, it was also benefit patients from detecting it. So we use the CRC+AA vs control groups of training set for further analysis. The performance of the combination of the two biomarker were evaluated by two strategies (**Table 1**). Strategy 1 involved the construction of a logistic regression model, with an estimated AUC value was 0.881 (95% CI: 0.840-0.922), the optimal sensitivity for CRC and specificity of 86.4% and 91.0%, respectively (**Table 1**). Strategy 2 was the 1/2 algorithm, which determined a positive measurement when the Ct of any single marker was less than its corresponding threshold. The cutoff was determined as Ct value corresponding to the maximum Youden index in the training dataset using CRC+ AA vs control data. The cutoff values were 48.2 and 48.4 for *NTMT1* and *MAP3K14-AS1*, respectively. At these cutoff, the two target sensitivities were 80.0% and 59.2%, with specificities of 92.8% and 97.0%, respectively (**Figure 6F**). The sensitivity and specificity of the combination of the two biomarkers were 86.4% and 91.0% respectively. Notably, strategy 2 yielded an identical sensitivity and specificity to strategy 1. Given that strategy 2 is considerably more straightforward for physicians to interpret test results in clinical practice, we have adopted the 1/2 algorithm as the combination algorithm for the dual-target test.


**Table 1.** Diagnostic performance of single biomarker and marker combination in training set.

Biomarker & combination	AUC (95% CI)	Sensitivity (CRC)	Sensitivity (CRC+AA)	Specificity	Cutoff	Combination method
<i>NTMT1</i>	0.852 (0.807-0.898)	80.0%	74.5%	92.8%	48.2	/
<i>MAP3K14-AS1</i>	0.761 (0.707-0.815)	59.2%	54.6%	97.0%	48.4	/
<i>NTMT1</i> & <i>MAP3K14-AS1</i>	0.881 (0.840-0.922)	86.4%	80.8%	91.0%	0.1491	Logistic regression
<i>NTMT1</i> & <i>MAP3K14-AS1</i>	/	86.4%	80.8%	91.0%	48.2, 48.4	1/2 algorithm

After the algorithm and cutoff was set, the validation set and all sample set were analyzed. The validation set had a 81.8% sensitivity and 92.5% specificity (**Figure 6G**) and the all sample set had a 84.8% sensitivity and 91.5% specificity (**Figure 6H**). The dual-target test had a higher sensitivity than that of any single biomarker and a slightly lower specificity in the three data sets (**Figure 6F-H**). It indicated that the combination of the two biomarkers were better than single biomarker.

### 3.7. Performance in subgroups of plasma samples

The performance of the dual-target test was evaluated in subgroups of all plasma samples. The test demonstrated a detection rate of 26.7% in non-AA samples and a detection rate of 32.0% in AA samples (**Figure 7A**). It exhibited sensitivities of 75.0%, 81.2% and 90.3% in stages I, II and III-IV of CRC samples, respectively (**Figure 7B**). The test exhibited specificities of 95.9%, 92.3%, 84.2% and 90.9% in healthy, NDD, ID and polyps samples, respectively (**Figure 7C**). The positive predictive value (PPV), negative predictive value (NPV) and accuracy for the dual-target test were 79.4%, 94.0% and 89.6%, respectively (**Figure 7D**).



**Figure 7.** Sensitivity, specificity in various clinical groups and other performance indicators of single biomarker and dual-target in total plasma sample set. (A-B) Sensitivity in Non-AA and AA groups (A), stages subgroups of CRC (B). (C) Specificity in healthy, NDD, ID and polyps groups. (D) PPV, NPV and accuracy of individual biomarkers and dual-target in CRC vs control groups. Control groups include healthy, NDD, ID, polyps, Non-AA and other cancers. Error bars represent 95% CI. NDD: Non-digestive disease, ID: Intestinal disease, AA: advanced adenoma.

With regard to the detection rates in adenoma and different stages of CRC, the dual-target test demonstrated superior performance compared to that of a single biomarker (Figure 7A-B). With respect to specificities in subgroups, the dual-target test exhibited a marginal decline in value compared to that of a single biomarker (Figure 7C). However, with regard to NPV and accuracy, the dual-target test demonstrated superior performance compared to that of a single biomarker (Figure 7D). With regard to PPV, the dual-target test exhibited a slight decline in performance relative to that of a single biomarker (Figure 7D).

#### 4. Discussion

It is commonly accepted that patients diagnosed with CRC at an early stage can be treated more effectively and have a better prognosis. Several stool DNA-based tests have been developed that demonstrate excellent performance in detecting CRCs at their early stages [23-26]. Blood sampling is more acceptable than stool sampling, but blood-based tests are less reported and usually exhibit lower sensitivities than stool-DNA tests, ranging from 47% to 87% [27]. This study presented a systematic pipeline for the discovery of methylation markers from scratch, test development, and evaluation in

437 training and validation plasma sets. The SADMP technique enhanced the ability to  
438 detect methylation signals. Following a comprehensive evaluation, the test obtained an  
439 overall sensitivity and specificity of 84.8% and 91.5%, respectively, for the detection of  
440 CRC at a volume of 2 ml plasma.

441 Adenoma and CRC displayed lower methylation levels overall, with the exception  
442 of regulatory regions (**Figure 2B and 3B**), a finding that has been reported in previous  
443 study [17]. Previous studies have focused on the CpG Island Methylator Phenotype  
444 (CIMP) found in CRC. This study found that tubular adenomas are common in the  
445 methy-L subclass, while villous adenomas are more often in methy-H subclass. Previous  
446 studies have indicated that CIMP is rarely found in tubular adenomas, but frequently in  
447 tubulovillous and villous adenomas [28], which is in accordance with this study. The  
448 large proportion of overlapping DMCs between cancer vs normal and adenoma vs  
449 normal indicated that many CpGs have undergone aberrant methylation events at the  
450 precancerous stage, which provides robust evidence for discovering the methylation  
451 markers for CRC early detection. It should be noted that the CRC markers are not  
452 necessarily applicable to adenomas, as a significant proportion of the DMCs in the  
453 Cancer vs Normal group were not present in the Adenoma vs Normal group, as  
454 illustrated in **Figure 3C**. This emphasises the importance of this study's inclusion of  
455 adenoma samples in the marker discovery set and the selection of DMCs in which  
456 cancers and adenomas overlap in a way that many other studies of CRC markers have  
457 not done.

458 Blood-based tests are more susceptible to interfering diseases and may result in a  
459 high false-positive rate. Therefore, specificity is a critical indicator. In the marker  
460 discovery step, 31 cancer types in the TCGA database and WBC were used to control the  
461 low methylation levels of candidate markers in other tissues and blood background,  
462 effectively attenuating the interference of unintended cfDNAs. In the assay development  
463 phase, we designed highly selective MSP primers that did not show normal  
464 amplification curves even when unmethylated DNAs were used as templates at  $10^7$   
465 copies (**Figure 5E and 5J**). These aforementioned measures guarantee a high specificity  
466 in plasma samples. Two combination algorithms were utilized to assess the performance  
467 of the dual-target test in the training set, and both algorithms indicated that the  
468 combined markers had better AUC values and higher sensitivities than any single  
469 marker (**Figure 6D and 6E**). However, the dual-target test showed a decreased  
470 specificity compared to both single markers, from 92.8% and 97.0% to 91.0% (**Figure 6H**),  
471 which was also observed in other studies [29,30]. When healthy individuals were  
472 selected as controls, the specificity improved to 95.9% (**Figure 7C**), which is comparable  
473 to the *Septine9* test [2]. These data demonstrate the excellent performance of the  
474 dual-target test in detecting CRC.

475 A number of studies [31-35] have demonstrated that the methylation levels of  
476 *NTMT1* (whose antisense chain counterpart is C9orf50) and *MAP3K14-AS1* can be  
477 employed for the screening and diagnosis of CRC. In particular, the study conducted by  
478 Sarah Ø Jensen et al [34] indicated that the C9orf50 methylation assay exhibited a  
479 plasma sensitivity of 76% and specificity of 91% for CRC. Ludovic Barault and  
480 colleagues [35] demonstrated that the *MAP3K14-AS1* methylation assay in plasma  
481 exhibited a sensitivity of 69.8% and a specificity of 100% for CRC. The dual-strand  
482 technique has been proven to enhance the performance of markers in previous studies  
483 [14,15]. This technique was also observed to be effective in our study. By detecting the  
484 methylation signals of *NTMT1* sense- and antisense-strand simultaneously, the Ct value  
485 of the dual-strand assay was able to shift forward by one compared to the single-strand  
486 assay (**Figure 5D**). In contrast to previous studies, the current study also included two  
487 MGB probes located downstream of forward and reverse primers of *MAP3K14-AS1*.  
488 During PCR strand extension, the polymerase enzymes cleaved the 5-primer sequence of  
489 probes and released two fluorescent groups. The dual-MGB probe technique doubled



490 the fluorescent signals when both probes shared the same channel, leading to an earlier  
491 Ct value similar to that of the dual-strand technique (**Figure 5I**). Serial dilution  
492 experiments confirmed the superiority of dual-MGB probes over one MGB probe  
493 (**Figure 5H-J**). These results suggest that applying the SADMP technique can be a  
494 feasible strategy to enhance the detection sensitivity of candidate markers.

495 Early diagnosis or screening techniques are essential to improve patient survival  
496 time, particularly when curable treatments are available. Studies have shown that the  
497 5-year survival rate of early detected CRC is almost 90%, while it was only 20% for  
498 advanced CRC [36]. The dual-target test showed a sensitivity of 75.0% and 81.2% for  
499 stage I and stage II CRC detection, notably, the dual-target test obtained a positive  
500 detection rate of 32.00% (8/25) for AA (**Figure 7B and 7C**), implying its ability to detect  
501 early CRC and precancerous lesions.

502 The current study has some limitations that may hamper the interpretation of these  
503 results. 1) Participants in this study were enrolled from a single center, which may bias  
504 these results. 2) the SADMP techniques may not applicable for all candidate markers.  
505 The dual-strand technique may be attempted when both sense and antisense strands are  
506 suitable for designing MSP primers, while the multiple MGB probe technique is limited  
507 by the amplicon length, which is usually less than 100 bp.  
508

## 509 5. Conclusions

510 In this study, we employed several public databases of adenomas and CRC for  
511 marker discovering, and ultimately identified two promising markers, *NTMT1* and  
512 *MAP3K14-AS1*. We then constructed the SADMP technology based on these two  
513 markers, which enhanced the sensitivity of the detection. The dual-target assay has a  
514 high sensitivity for AA and early stage CRC, and its clinical application value merits  
515 further investigation.

516 **Supplementary Materials:** The following supporting information can be downloaded at:  
517 [www.mdpi.com/xxx/s1](http://www.mdpi.com/xxx/s1), Figure S1: The methylation status of candidate markers verified by Sanger  
518 sequencing; Table S1: The clinical features of training and validation cohorts used in this study;  
519 Table S2: The information of primers for Sanger sequencing in this study; Table S3: The  
520 information of primers and MGB probes used in this study; Table S4: The amplification system of  
521 the MSP.

522 **Author Contributions:** Conception: YT Z, ZJ W and SC W; Supervision: YT Z and SC W; Funding  
523 acquisition: YT Z; Project administration: ZJ W; Methodology, Resources, Data curation: QN Y, X  
524 L, X L, SL D, XP L and T Z; Software, Validation, Formal analysis: DH Z; Writing-original draft:  
525 YT Z; Writing-review & editing: YT Z, ZJ W and SC W. All authors have read and agreed to the  
526 published version of the manuscript.

527 **Funding:** This study was supported by science and technology project of Henan Province  
528 (232102310028).

529 **Institutional Review Board Statement:** The study was conducted in accordance with the  
530 Declaration of Helsinki, and approved by the Ethics Committee of the First Affiliated Hospital of  
531 Zhengzhou University (approval number: 2022-KY-0631-002).

532 **Informed Consent Statement:** Informed consent was obtained from all subjects involved in the  
533 study.

534 **Data Availability Statement:** The datasets (GSE77954, GSE101764, GSE131013, GSE164811,  
535 GSE193535, GSE129364, GSE139404, GSE107352, GSE75546, GSE77965, GSE199057, GSE68060,  
536 GSE48684, GSE40279 and GSE122126) supporting the conclusions of this article are available in the  
537 Gene Expression Omnibus database (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi>). The  
538 E-MTAB-6450 data is available in EMBL biostudies  
539 (<https://www.ebi.ac.uk/biostudies/arrayexpress>). The source code and intermediate data can be  
540 accessed from git-hub (<https://github.com/amsinfor/CRC-methylation>).

541

**Acknowledgments:** We thank Dr. Kangkang wan for the assistance in MSP designing and data analysis in this work.

542

543

**Conflicts of Interest:** The authors declare no conflicts of interest.

544

**Supplemental table 1.** The clinical features of training and validation cohorts used in this study.

	Training set								Validation set							
	Healthy n=115	NDD n=123	ID n=65	Polyps n=14	Non-AA n=10	AA n=16	CRC n=125	Other cancers n=6	Healthy n=57	NDD n=60	ID n=30	Polyps n=6	Non-AA n=5	AA n=9	CRC n=66	Other cancers n=2
Sex (n, %)																
Male	65 (56.5%)	63 (51.2%)	38 (58.5%)	10 (71.4%)	7 (70.0%)	7 (43.8%)	70 (56.0%)	4 (66.7%)	25 (43.9%)	39 (65.0%)	12 (40.0%)	3 (50.0%)	3 (60.0%)	4 (44.4%)	37 (56.1%)	1 (50.0%)
Female	50 (43.5%)	60 (48.8%)	27 (41.5%)	4 (28.6%)	3 (30.0%)	9 (56.3%)	55 (44.0%)	2 (33.3%)	32 (56.1%)	21 (35.0%)	18 (60.0%)	3 (50.0%)	2 (40.0%)	5 (55.6%)	29 (43.9%)	1 (50.0%)
Age																
Median	40	52	62	66	65	56	64	65	40	50	58	64	53	54	64	69
Range	25-45	33-80	33-79	39-83	52-73	43-76	33-86	41-80	25-43	30-60	40-80	44-74	49-67	38-76	33-82	59-79
TNM Stage (n, %)																
I							20 (16.0%)								8 (12.1%)	
II							33 (26.4%)								15 (22.7%)	
III							37 (29.6%)								23 (34.8%)	
IV							2 (1.6%)								0 (0.0%)	
Na							33 (26.4%)								20 (30.3%)	

547

548

549

**Supplemental Table 2.** The information of primers for Sanger sequencing in this study.

550

Target	Strand	Methylation template-specific		Sequence
		/Unmethylation template-specific	Primer type	
<i>NTMT1</i>	Sense	Methylation template-specific	Forward	5'-TATCGGAAATGATTCGTGTTTCG-3'
			Reverse	5'-CAAAACCTAAAAACGTGAACGC-3'
		Unmethylation template-specific	Forward	5'-TTATTGGAAATGATTTGGCTTTG-3'
	Antisense		Reverse	5'-ACCAAAACCTAAAAACACAAACAC-3'
		Methylation template-specific	Forward	5'-CGGGTCGTGCGGAAGC-3'
			Reverse	5'-AAATCCTCCCTAACCACGAGC-3'
<i>MAP3K14-AS1</i>	Antisense	Unmethylation template-specific	Forward	5'-TGGTCGGTTGTGTGGAAGTG-3'
			Reverse	5'-CAAAATCGTCCCTAACCACACA-3'
		Methylation template-specific	Forward	5'-ATAGAGTTTCGGTTTGTATGGGG-3'*
		Reverse	5'-ATCGACCTACCTTTCAAATACCG-3'	
		Forward	5'-GATAGAGTTTTCGGTTTGTATGGGG-3'	
		Reverse	5'-AAATCAACCTACCTTTCAAATACCA-3'	

551

552

**Supplemental Table 3.** The information of primers and MGB probes used in this study.

Target	Primers	Sequence	Amplification region	Length
<i>ACTB</i>	forward	5'-GGGATAGTTAGGTTAGATGG-3'	chr7: 5528763-5528861	99 bp
	reverse	5'-ACACAATAAATCTAAACA-3'		
	MGB probe	5'-CATCCCAAAACCCCAAC-3'		
<i>NTMT1</i>	sense forward	5'-GTGGTTTCGGTTTTTCGGC-3'	Chr9:129620070-129620170	101 bp
	sense reverse	5'-CCCCGACTTCTTAAACGCC-3'		
	sense MGB probe	5'-ATTACGGAATTTGTTGGGGAGGAG-3'		
	antisense forward	5'-CGGCTCGTTTCGGGAATC-3'	Chr9:129620188-129620251	64 bp
	antisense reverse	5'-TCCTCCGAAAACGCTCGTG-3'		
	antisense MGB probe	5'-CAAACCCTAACTACCTAAACGCC-3'		
<i>MAP3K14-AS1</i>	antisense forward	5'-TGGGTGATAGGTGGGAGCG-3'	Chr17:45261937-45262012	77 bp
	antisense reverse	5'-TCCCCCTCTCACTTTCGCTT-3'		
	MGB probe 1	5'-TCGAGCGTTCGGGGGC-3'		
	MGB probe 2	5'-CCCGCCTACCCCAACCC-3'		

553

554

555

Supplemental Table 4. The amplification system of the MSP.

Components	Volume (ul)
20*HA buffer (Ammunition Life-tech, Wuhan)	2.5
25mM dNTP Mixture (yisheng, Wuhan)	0.4
High Affinity HotStart Taq (5U/ $\mu$ L) (TianGen, Beijing)	0.6
TE (Sangon Biotech, Shanghai)	5.16
Forward primer of <i>ACTB</i> (100 $\mu$ M)	0.1
Reverse primer of <i>ACTB</i> (100 $\mu$ M)	0.1
Probe of <i>ACTB</i> (100 $\mu$ M)	0.1
Forward primer of <i>NTMT1</i> sense (100 $\mu$ M)	0.1
Reverse primer of <i>NTMT1</i> sense (100 $\mu$ M)	0.1
Probe of <i>NTMT1</i> sense (100 $\mu$ M)	0.1
Forward primer of <i>NTMT1</i> antisense (100 $\mu$ M)	0.1
Reverse primer of <i>NTMT1</i> antisense (100 $\mu$ M)	0.1
Probe of <i>NTMT1</i> antisense (100 $\mu$ M)	0.1
Forward primer of <i>MAP3K14-AS1</i> (100 $\mu$ M)	0.1
Reverse primer of <i>MAP3K14-AS1</i> (100 $\mu$ M)	0.1
Probe 1 of <i>MAP3K14-AS1</i> (100 $\mu$ M)	0.12
Probe 2 <i>MAP3K14-AS1</i> (100 $\mu$ M)	0.12
Template DNA	40
Total	50

556  
557

558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576

## 577 References

- 578 1. Powrózek T, Krawczyk P, Kucharczyk T, Milanowski J. Septin 9 promoter region methylation in free circulating  
579 dna—potential role in noninvasive diagnosis of lung cancer: preliminary report. *Med Oncol* 2014;31: 917. doi:  
580 10.1007/s12032-014-0917-4
- 581 2. Lamb YN, Dhillon S. Epi procolon® 2.0 ce: a blood-based screening test for colorectal cancer. *Mol Diagn Ther* 2017;21: 225-32.  
582 doi: 10.1007/s40291-017-0259-y
- 583 3. Sun J, Fei F, Zhang M, Li Y, Zhang X, Zhu S, et al. The role of msept9 in screening, diagnosis, and recurrence monitoring of  
584 colorectal cancer. *Bmc Cancer* 2019; 19: 450. doi: 10.1186/s12885-019-5663-8
- 585 4. Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A. Epigenetics of colorectal cancer: biomarker and therapeutic  
586 potential. *Nat Rev Gastroenterol Hepatol* 2020;17(2):111-130. doi: 10.1038/s41575-019-0230-y.
- 587 5. Church TR, Wandell M, Lofton-Day C, Mongin SJ, Burger M, Payne SR, et al. Prospective evaluation of methylated SEPT9 in  
588 plasma for detection of asymptomatic colorectal cancer. *Gut* 2014; 63(2):317-25. doi: 10.1136/gutjnl-2012-304149.
- 589 6. Nassar FJ, Msheik ZS, Nasr RR, Temraz SN. Methylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis,  
590 prognosis, and prediction. *Clin Epigenetics* 2021;13(1):111. doi: 10.1186/s13148-021-01095-5.
- 591 7. Li B, Huang H, Huang R, Zhang W, Zhou G, Wu Z, et al. Sept9 gene methylation as a noninvasive marker for hepatocellular  
592 carcinoma. *Dis Markers* 2020; 2020: 6289063. doi: 10.1155/2020/6289063
- 593 8. Cao CQ, Chang L, Wu Q. Circulating methylated septin 9 and ring finger protein 180 for noninvasive diagnosis of early  
594 gastric cancer. *Transl Cancer Res* 2020; 9: 7012-21. doi: 10.21037/tcr-20-1330
- 595 9. Jiao X, Zhang S, Jiao J, Zhang T, Qu W, Muloye GM, et al. Promoter methylation of sept9 as a potential biomarker for early  
596 detection of cervical cancer and its overexpression predicts radioresistance. *Clin Epigenetics* 2019;11: 120. doi:  
597 10.1186/s13148-019-0719-9
- 598 10. Matsui S, Kagara N, Mishima C, Naoi Y, Shimoda M, Shimomura A, et al. Methylation of the sept9\_v2 promoter as a novel  
599 marker for the detection of circulating tumor dna in breast cancer patients. *Oncol Rep* 2016; 36: 2225-35. doi:  
600 10.3892/or.2016.5004
- 601 11. Song P, Wu LR, Yan YH, Zhang JX, Chu T, Kwong LN, et al. Limitations and opportunities of technologies for the analysis of  
602 cell-free DNA in cancer diagnostics. *Nat Biomed Eng* 2022;6(3):232-245. doi: 10.1038/s41551-021-00837-3.
- 603 12. Babayan A, Pantel K. Advances in liquid biopsy approaches for early detection and monitoring of cancer. *Genome Med* 2018;  
604 10: 21. doi: 10.1186/s13073-018-0533-6
- 605 13. Li LC, Dahiya R. Methprimer: designing primers for methylation pcrs. *Bioinformatics* 2002;18: 1427-31. doi:  
606 10.1093/bioinformatics/18.11.1427
- 607 14. Jensen SØ, Øgaard N, Nielsen HJ, Bramsen JB, Andersen CL. Enhanced performance of dna methylation markers by  
608 simultaneous measurement of sense and antisense dna strands after cytosine conversion. *Clin Chem* 2020; 66: 925-33. doi:  
609 10.1093/clinchem/hvaa100
- 610 15. Faaborg L, Fredslund AR, Waldstrøm M, Høgdall E, Høgdall C, Adimi P, et al. Analysis of hoxa9 methylated ctDNA in ovarian  
611 cancer using sense-antisense measurement. *Clin Chim Acta* 2021; 522: 152-7. doi: 10.1016/j.cca.2021.08.020
- 612 16. Aryee MJ, Jaffe AE, Corrada-Bravo H, Ladd-Acosta C, Feinberg AP, Hansen KD, et al. Minfi: a flexible and comprehensive  
613 bioconductor package for the analysis of infinium dna methylation microarrays. *Bioinformatics* 2014; 30: 1363-9. doi:  
614 10.1093/bioinformatics/btu049
- 615 17. Luo Y, Wong CJ, Kaz AM, Dzieciatkowski S, Carter KT, Morris SM, et al. Differences in dna methylation signatures reveal  
616 multiple pathways of progression from adenoma to colorectal cancer. *Gastroenterology* 2014; 147: 418-29. doi:  
617 10.1053/j.gastro.2014.04.039
- 618 18. Hannum G, Guinney J, Zhao L, Zhang L, Hughes G, Sada S, et al. Genome-wide methylation profiles reveal quantitative  
619 views of human aging rates. *Mol Cell* 2013; 49: 359-67. doi: 10.1016/j.molcel.2012.10.016
- 620 19. Moss J, Magenheimer J, Neiman D, Zemmour H, Loyfer N, Korach A, et al. Comprehensive human cell-type methylation atlas  
621 reveals origins of circulating cell-free dna in health and disease. *Nat Commun* 2018; 9: 5068. doi: 10.1038/s41467-018-07466-6
- 622 20. Li R, Qu B, Wan K, Lu C, Li T, Zhou F, et al. Identification of two methylated fragments of an sdc2 cpg island using a sliding  
623 window technique for early detection of colorectal cancer. *Febs Open Bio.* (2021) 11: 1941-52. doi: 10.1002/2211-5463.13180
- 624 21. Zhang L, Dong L, Lu C, Huang W, Yang C, Wang Q, et al. Methylation of SDC2/TFPI2 and Its Diagnostic Value in Colorectal  
625 Tumorous Lesions. *Front Mol Biosci.* 2021;8:706754. doi: 10.3389/fmolb.2021.706754.
- 626 22. Bian Y, Gao Y, Lu C, Tian B, Xin L, Lin H, et al. Genome-wide methylation profiling identified methylated KCNA3 and  
627 OTOP2 as promising diagnostic markers for esophageal squamous cell carcinoma. *Chin Med J (Engl)* 2023; doi:  
628 10.1097/CM9.0000000000002832.
- 629 23. Wang Z, Shang J, Zhang G, Kong L, Zhang F, Guo Y, et al. Evaluating the clinical performance of a dual-target stool dna test  
630 for colorectal cancer detection. *J Mol Diagn* 2022; 24: 131-43. doi: 10.1016/j.jmoldx.2021.10.012
- 631 24. Imperiale TF, Ransohoff DF, Itzkowitz SH, Levin TR, Lavin P, Lidgard GP, et al. Multitarget stool dna testing for  
632 colorectal-cancer screening. *N Engl J Med* 2014;370: 1287-97. doi: 10.1056/NEJMoa1311194
- 633 25. Zhao G, Liu X, Liu Y, Li H, Ma Y, Li S, et al. Aberrant dna methylation of sept9 and sdc2 in stool specimens as an integrated  
634 biomarker for colorectal cancer early detection. *Front Genet* 2020; 11: 643. doi: 10.3389/fgene.2020.00643

- 
- 635 26. Oh TJ, Oh HI, Seo YY, Jeong D, Kim C, Kang HW, et al. Feasibility of quantifying sdc2methylation in stool dna for early  
636 detection of colorectal cancer. *Clin Epigenetics* 2017; 9: 126. doi: 10.1186/s13148-017-0426-3
- 637 27. Nassar FJ, Msheik ZS, Nasr RR, Temraz SN. Methylated circulating tumor dna as a biomarker for colorectal cancer diagnosis,  
638 prognosis, and prediction. *Clin Epigenetics* 2021; 13: 111. doi: 10.1186/s13148-021-01095-5
- 639 28. Kakar S, Deng G, Cun L, Sahai V, Kim YS. CpG island methylation is frequently present in tubulovillous and villous  
640 adenomas and correlates with size, site, and villous component. *Hum Pathol* 2008; 39: 30-6. doi:  
641 10.1016/j.humpath.2007.06.002
- 642 29. Zhao G, Li H, Yang Z, Wang Z, Xu M, Xiong S, et al. Multiplex methylated dna testing in plasma with high sensitivity and  
643 specificity for colorectal cancer screening. *Cancer Med* 2019; 8: 5619-28. doi: 10.1002/cam4.2475
- 644 30. Bagheri H, Mosallaei M, Bagherpour B, Khosravi S, Salehi AR, Salehi R. Tfp2 and ndrg4 gene promoter methylation analysis  
645 in peripheral blood mononuclear cells are novel epigenetic noninvasive biomarkers for colorectal cancer diagnosis. *J Gene  
646 Med* 2020;22: e3189. doi: 10.1002/jgm.3189
- 647 31. Cao Y, Zhao G, Yuan M, Liu X, Ma Y, Cao Y, et al. KCNQ5 and C9orf50 Methylation in Stool DNA for Early Detection of  
648 Colorectal Cancer. *Front Oncol* 2021; 29;10:621295. doi: 10.3389/fonc.2020.621295.
- 649 32. Zhang Y, Wu Q, Xu L, Wang H, Liu X, Li S, et al. Sensitive detection of colorectal cancer in peripheral blood by a novel  
650 methylation assay. *Clin Epigenetics* 2021;13(1):90. doi: 10.1186/s13148-021-01076-8.
- 651 33. Jensen SØ, Øgaard N, Ørntoft MW, Rasmussen MH, Bramsen JB, Kristensen H, et al. Novel DNA methylation biomarkers  
652 show high sensitivity and specificity for blood-based detection of colorectal cancer-a clinical biomarker discovery and  
653 validation study. *Clin Epigenetics* 2019;11(1):158. doi: 10.1186/s13148-019-0757-3.
- 654 34. Barault L, Amatu A, Siravegna G, Ponzetti A, Moran S, Cassingena A, et al. Discovery of methylated circulating DNA  
655 biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer. *Gut* 2018;  
656 67(11):1995-2005. doi: 10.1136/gutjnl-2016-313372.
- 657 35. Huang H, Cao W, Long Z, Kuang L, Li X, Feng Y, et al. DNA methylation-based patterns for early diagnostic prediction and  
658 prognostic evaluation in colorectal cancer patients with high tumor mutation burden. *Front Oncol* 2023;12:1030335. doi:  
659 10.3389/fonc.2022.1030335.
- 660 36. Ladabaum U, Dominitz JA, Kahi C, Schoen RE. Strategies for colorectal cancer screening. *Gastroenterology* 2020; 158: 418-32.  
661 doi: 10.1053/j.gastro.2019.06.043
- 662

663 **Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual  
664 author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury  
665 to people or property resulting from any ideas, methods, instructions or products referred to in the content.